Clinical trial
Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of…
NCT00002429 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00002429 |
|---|---|
| Title | Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen |
| Official title | Evaluation of HIV RNA Suppression Produced by a Triple Combination Regimen Containing an Enteric Coated Formulation of Didanosine (ddI EC) Administered Once Daily Compared to a Reference Combination Regimen |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Lamivudine/Zidovudine, Nelfinavir mesylate, Stavudine, Didanosine |
| Enrollment | 500 |
| Start date | Jul 1, 1999 |
| Primary completion | Jan 1, 2001 |
| Completion | Jan 1, 2001 |
| First posted | Aug 31, 2001 |
| Last update posted | May 4, 2011 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: